News

/News

BioCT launches feature-rich career portal

You asked for it and BioCT is delivering! The new BioCT Career Portal provides a feature-rich, dedicated resource to connect Connecticut’s bioscience employers and today’s talent, seamlessly via one easy-to-use platform. more

By |February 13th, 2018|News|0 Comments

BioCT welcomes new member Celldex

Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Their pipeline includes antibodies, antibody-drug conjugates and other protein-based therapeutics derived from a broad set of complementary technologies which have the ability to engage the human immune system and/or directly inhibit tumors to treat specific types of cancer or other diseases. more

By |February 13th, 2018|News|0 Comments

JAX explores causes of type 2 diabetes

A Jackson Laboratory scientist based in Farmington is conducting a large-scale survey of cells from prediabetic, diabetic and normal patients to discover new treatments for type 2 diabetes. Type 2 diabetes is a worldwide epidemic. Incidence has quadrupled since 1980 to more than 422 million people — 30 million in the U.S. alone. Current therapies are not sufficient to stop the disease from progressing and causing subsequent medical problems that may include vision loss, heart disease, stroke, kidney failure, amputation of feet or legs, and premature death. more

By |February 13th, 2018|News|0 Comments

Boehringer Ingelheim announces CEO transition

Boehringer Ingelheim announced today that Paul Fonteyne, U.S. President and CEO will retire after 15 years of committed service on December 31, 2018. Wolfgang Baiker, M.D, Ph.D, M.B.A., has been appointed to succeed him, effective March 1, 2018. Dr. Baiker, currently Senior Vice President, Human Pharma Supply & Global Quality and Head of the Biopharma Business Unit, joined Boehringer Ingelheim in 1989 as Section Head for Clinical Development in Biberach, Germany. Since then, Dr. Baiker has served in a number of senior leadership roles across several critical business functions. more

By |February 13th, 2018|News|0 Comments

New name, new leader for CT bioscience

This past October, when Dawn Hocevar assumed her new role as president and CEO of CURE — Connecticut's membership association of bioscience companies — she brought more than her decades of experience in the sector to the state, she also brought a new name for the organization, BioCT. "I wanted a name that clearly describes our role and who we are in the bio industry," said Hocevar, who has worked in bioscience hotspots from San Francisco to Boston. more

By |February 13th, 2018|News|0 Comments

ABCT announces 2018 cohort of life science startups

ABCT, Connecticut's newest life science startup accelerator and a CTNext partner program, has announced the new cohort accepted to its 2018 cycle. The ABCT team has identified and invited 12 promising innovations and passionate scientific and technical minds to join the inaugural 2018 Class of the ABCT program and to accelerate the development of their technologies into successful businesses. Ventures technologies were developed at UConn, Yale, Quinnipiac, Weill Cornell, NYU, and Columbia research institutions. All of the accepted startups have already received funding and are now seeking broader mentor networks for fundraising and team building. more

By |February 6th, 2018|News|0 Comments

BioCT welcomes new member Hughes BioPharma

Hughes BioPharma Advisers offers expertise and support in strategy, marketing, and regulatory compliance. The Hughes team offers key skills including digital health, health tech, biologics, small molecule, rare diseases, oncology, cardiovascular, neurology and more. more

By |February 6th, 2018|News|0 Comments

UConn technique identifies patients’ tumor profiles

A team of UConn Health researchers are developing a technology that rapidly identifies a patient's unique tumor mutation profile to help physicians better guide cancer treatment with immunotherapies. In a recent issue of Proteomics, Veneta Qendro (the lead author),  David Han (associate professor of cell biology), and team describe their platform technology, known as a Genomics Driven Immunoproteomics or GDI, which allows rapid identification of personalized tumor mutation profiles that are recognized by cancer patients’ own immune system. more

By |February 6th, 2018|News|0 Comments

Cara initiates Phase 3 trial of KORSUVA™

Cara Therapeutics has initiated it first pivotal Phase 3 efficacy trial of KORSUVA™ (CR845/difelikefalin) injection in hemodialysis patients suffering from moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP) in the United States. The FDA granted Breakthrough Therapy Designation to KORSUVA™ injection for this indication, for which there are currently no approved therapies in the U.S. more

By |February 6th, 2018|News|0 Comments

Yale studies secrets of longevity protein

Named after the Greek goddess who spun the thread of life, Klotho proteins play an important role in the regulation of longevity and metabolism. In a recent Yale-led study, researchers revealed the three-dimensional structure of one of these proteins, beta-Klotho, illuminating its intricate mechanism and therapeutic potential. The study findings, published in Nature, could have implications for therapies developed to treat a wide range of medical conditions, including diabetes, obesity, and certain cancers, the researchers said. more

By |February 6th, 2018|News|0 Comments